Company Overview

In March 2018, IQ-AI Ltd acquired Imaging Biometrics, LLC, a Wisconsin USA-based healthcare imaging software company. In addition to providing regulatory consulting services, Imaging Biometrics supplies medical technology solutions and has a strong neuroimaging product portfolio. This is the second acquisition made by IQ-AI in the medical imaging space after acquiring Stone Checker Software Ltd in 2017.

Please find more information on the Imaging Biometrics website www.imagingbiometrics.com and the StoneChecker website www.stonechecker.com .

News & Announcements Highlights

Shareholder Information

IQ-AI Ltd ordinary shares are traded on the Standard List of the London Stock Exchange. The IQ-AI Ltd ticker code is IQAI
There are no restrictions on the transfer of shares.

Trevor Brown

Trevor Brown is the Chief Executive Director of IQ-AI Ltd. Most recently a director of Feedback plc, MRS plc, and Remote Monitored Systems plc, Trevor is currently a director of Chamberlin plc and Braveheart Investment Group plc.

VINOD KAUSHAL

Vinod is a non-executive director on the board of IQ-AI Ltd. Vinod is a well-seasoned healthcare industry executive with nearly 30 years’ experience in predominantly commercial and general management roles. He has worked nationally, regionally and globally for a number of blue chip and SME companies.

Having been part of the team which orchestrated the international launch of Losec®/Prilosec® at Astra to its place as the global No. 1 selling pharmaceutical, Vinod was Head of Global Marketing at Novo Nordisk, Senior Vice President Fresenius Kabi, Vice President of Amersham/GE Health’s Neurology business, Vice President at Royal Numico/Danone and CEO of SPL amongst other pivotal roles.

Since leaving Big Pharma, Vinod has recently been focused on entrepreneurial activities with a number of successful SMEs in the Pharma/Healthcare space. With an impressive deal sheet to his name, Vinod has been involved in various IP and business acquisitions. His career has seen him relate to investors on several global stock exchanges and he is an accomplished external speaker. Vinod holds a BSc (Hons) in Biochemistry from Warwick University and a MBA from Henley Business School.

Brett Skelly

Brett has been working in the financial sector for GBAC Limited for over 16 years carrying out various roles including preparing accounts and auditing a wide range of large and SME companies as well as preparing management information and forecasts. He has been involved in developing business plans and also been involved in a number of company sales and MBOs over the years.

In December 2017, Brett became the outsourced financial controller of Braveheart Investment Group Plc and is also the outsourced financial controller at Anticus Partners Limited.

Michael Schmainda

Michael has a 20-year history of successfully building global medical imaging businesses including Prism Clinical Imaging and Imaging Biometrics. As co-founder of IB, he has overseen all aspects of the company's development, operation, and growth since its inception. He has established strong collaborative relationships with leaders in the medical imaging field who drive new product development and has led the translation and commercialisation of sophisticated imaging solutions, achieved regulatory approvals in the US and Europe, and global product adoption.

Michael's career began with 3M Company, a company renowned for bringing new products to market, where he held leadership roles across multiple industries including the life science sector. Prior to IB, Michael was a foundational member of Prism Clinical Imaging, secured the initial investment for the company, and served as president and COO.

Company Advisors

Peterhouse Capital Limited
New Liverpool House, 15 Eldon Street, London EC2M 7LD

PKF Littlejohn LLP
15 Westferry Circus, London E14 4HD

Barclays Bank plc
39 / 41 Broad Street, St Helier, Jersey JE4 8PU

Share Registrars Ltd
Suite E, First Floor, 9 Lion & Lamb Yard, Farnham, Surrey GU9 7LL

SIGNIFICANT SHAREHOLDERS

As at 05 May 2022, as far as the Directors are aware, the following shareholders
are interested in 3% or more of the issued share capital of the Company.

Total shares in issue: 182,621,390 Ordinary Shares of £0.01 each